Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
F Li, C Li, X Cai, Z **e, L Zhou, B Cheng, R Zhong… - …, 2021 - thelancet.com
Background The responses of cancer patients to immune checkpoint inhibitors (ICIs) vary in
success. CD8+ tumor infiltrating lymphocytes (TILs) play a key role in killing tumor cells. This …
success. CD8+ tumor infiltrating lymphocytes (TILs) play a key role in killing tumor cells. This …
[HTML][HTML] The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of …
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …
with NSCLC and have led to unprecedented improvements in response rates and survival in …
[HTML][HTML] Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1–positive advanced …
Introduction In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS)
versus docetaxel in patients with previously treated, advanced NSCLC with programmed …
versus docetaxel in patients with previously treated, advanced NSCLC with programmed …
The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis
Y Wu, J Xu, C Du, Y Wu, D **a, W Lv, J Hu - Frontiers in oncology, 2019 - frontiersin.org
Background: Despite an increasing understanding about tumor mutation burden (TMB) in
cancer immunity and cancer immunotherapy, the comprehensive cognition between TMB …
cancer immunity and cancer immunotherapy, the comprehensive cognition between TMB …
[HTML][HTML] Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer
LM Sholl - Modern Pathology, 2022 - Elsevier
Immunotherapy, including use of checkpoint inhibitors against PD-1, PD-L1, and CTLA-4,
forms the backbone of oncologic management for the majority of non-small cell lung …
forms the backbone of oncologic management for the majority of non-small cell lung …
Soluble PD-L1 and circulating CD8+ PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients
G Mazzaschi, R Minari, A Zecca, A Cavazzoni, V Ferri… - Lung Cancer, 2020 - Elsevier
Introduction Upfront criteria to foresee immune checkpoint inhibitors (ICIs) efficacy are far
from being identified. Thus, we integrated blood descriptors of pro-inflammatory …
from being identified. Thus, we integrated blood descriptors of pro-inflammatory …
CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors
S Karaki, C Blanc, T Tran… - Journal for …, 2021 - pmc.ncbi.nlm.nih.gov
Background Resident memory T lymphocytes (TRM) are located in tissues and play an
important role in immunosurveillance against tumors. The presence of TRM prior to …
important role in immunosurveillance against tumors. The presence of TRM prior to …
Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment
K Iwahori - Tumor Microenvironment: Hematopoietic Cells–Part A, 2020 - Springer
In the tumor microenvironment, CD8+ T cells play a major role in tumor immunity. CD8+ T
cells differentiate to cytotoxic T cells, traffic into the tumor microenvironment, and exhibit …
cells differentiate to cytotoxic T cells, traffic into the tumor microenvironment, and exhibit …
Progresses in biomarkers for cancer immunotherapy
X Lin, C Zong, Z Zhang, W Fang, P Xu - MedComm, 2023 - Wiley Online Library
Currently, checkpoint inhibitor‐based immunotherapy has emerged as prevailing treatment
modality for diverse cancers. However, immunotherapy as a first‐line therapy has not …
modality for diverse cancers. However, immunotherapy as a first‐line therapy has not …
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
K Hummelink, V van der Noort, M Muller… - Clinical Cancer …, 2022 - aacrjournals.org
Purpose: Durable clinical benefit to PD-1 blockade in non–small cell lung cancer (NSCLC)
is currently limited to a small fraction of patients, underlining the need for predictive …
is currently limited to a small fraction of patients, underlining the need for predictive …